Dihexa and HGF/c-Met: The Synaptogenesis Research Explained

HGF (hepatocyte growth factor — a multifunctional growth factor originally characterized for its role in liver regeneration but subsequently found to be expressed in multiple tissues including the brain, where it is produced by neurons and astrocytes) and its receptor c-Met (the HGF receptor — a receptor tyrosine kinase expressed on neurons, particularly in hippocampal pyramidal neurons and cortical neurons where it drives synaptogenesis and cell survival) form a signaling axis that was identified as a neuroplasticity regulator in published research in the 2000s.

Published research on HGF/c-Met in the hippocampus documented that activation of c-Met drives dendritic spine formation (the structural basis of new synaptic connections — each spine on a dendrite is the postsynaptic structure of one synapse), axonal growth, and neuroprotection against excitotoxic damage. This positioned HGF/c-Met as a direct driver of the structural plasticity that underlies learning and memory.

The Joseph Harding laboratory at Washington State University identified HGF/c-Met as a target for cognitive enhancement research and began a systematic medicinal chemistry program to develop small molecules and peptides that could activate c-Met in the brain with sufficient potency and CNS penetration for in vivo research.

Dihexa's development followed from research on a simpler compound: angiotensin IV (AT IV — a hexapeptide fragment of angiotensin II, the blood pressure regulatory hormone — originally characterized for its cardiovascular effects but subsequently found to produce cognitive enhancement effects in published animal research through mechanisms that did not involve angiotensin receptors).

Published research in the 1990s and 2000s documented that angiotensin IV enhanced memory consolidation in animal models, and that this effect was independent of AT1 and AT2 receptors. The mechanism remained unknown until the Harding laboratory identified HGF/c-Met as the target — angiotensin IV binds to a site on the c-Met receptor and activates it to drive synaptogenesis.

Dihexa was developed by modifying angiotensin IV's structure to increase CNS penetration, metabolic stability, and potency at c-Met. The resulting compound — N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — retained the c-Met activating properties of angiotensin IV while gaining dramatically improved pharmacological characteristics, including the ability to penetrate the blood brain barrier after systemic administration.

The finding that generated the most attention in the published Dihexa literature was a potency comparison: in hippocampal slice preparations measuring synaptogenesis, Dihexa produced measurable increases in dendritic spine density at concentrations approximately 7 to 10 orders of magnitude lower (10 million to 10 billion times lower) than other compounds tested for the same endpoint in the same preparation.

This extraordinary potency, if replicable and translatable to in vivo conditions, would be mechanistically significant for two reasons. First, it suggests that the c-Met activation pathway is unusually efficient for driving synaptogenesis compared to other mechanisms that were tested. Second, it suggests that in vivo effects might be achievable at doses far below those required for compounds acting through other mechanisms.

Caveats for interpreting this finding: the comparison was between Dihexa and other compounds at fixed concentrations in a specific in vitro preparation. In vivo bioavailability, distribution, and receptor occupancy dynamics complicate direct translation from in vitro potency to in vivo dose requirements. The 7-10 orders of magnitude comparison reflects in vitro pharmacology under controlled conditions, not necessarily in vivo dose-response.

Published Dihexa research in animal behavioral models documents cognitive enhancement effects in tasks that measure hippocampal-dependent spatial memory. The Morris water maze (a spatial memory task requiring animals to learn the location of a hidden escape platform based on room cues), the novel object recognition test, and other validated memory assays have been used to document Dihexa effects in published research from the Harding laboratory.

In aged animals with cognitive impairment — a model population with established HGF/c-Met pathway deficits in the hippocampus — Dihexa produced substantial improvements in memory task performance in published studies. The magnitude of improvement in some protocols approached the performance levels of young, unimpaired animals — a result that, if generalizable, would be among the more striking cognitive restoration findings in the animal literature.

Peripherally administered Dihexa (systemic injection or nasal administration) produced brain-level effects in published research, confirming adequate CNS penetration. The blood brain barrier penetration was designed into the compound through the modification of the angiotensin IV scaffold.

c-Met activation by Dihexa initiates a signaling cascade that ultimately drives cytoskeletal reorganization in dendritic spines. PI3K-Akt signaling (phosphatidylinositol 3-kinase and its downstream effector Akt — a pro-survival and growth-promoting pathway activated by receptor tyrosine kinases including c-Met) activates Rac1 (a small GTPase — a molecular switch that regulates actin polymerization in dendritic spines and drives the structural changes required for new spine formation).

Rac1-driven actin polymerization produces the physical expansion of the dendritic spine head that is required for new synapse formation. This is the same basic process that BDNF drives through TrkB signaling — both converge on actin cytoskeleton remodeling in spines — but through different upstream signaling cascades. The convergence on common downstream actin dynamics explains why both BDNF-driven and HGF/c-Met-driven pathways produce similar structural outcomes (spine density increase) despite different receptor-level mechanisms.

Published research from the Harding laboratory has characterized this signaling pathway in detail, providing the mechanistic foundation that connects Dihexa's pharmacology to the observed behavioral and structural outcomes.

Dihexa is entirely preclinical at the published evidence level. No published human clinical trial data exists for any cognitive, safety, or pharmacokinetic endpoint in human subjects. All published efficacy data comes from in vitro preparations and animal behavioral models.

This does not diminish the scientific quality of the published research — the Harding laboratory's work is published in peer-reviewed journals and has been replicated at the pathway level if not yet independently in behavioral studies. But the gap between compelling preclinical data and established human efficacy is the standard challenge of translational neuroscience, where animal-to-human translation failures are common.

For researchers, the honest framing is: Dihexa has one of the most mechanistically interesting published profiles in cognitive research, with a validated molecular target (c-Met), documented pathway mechanism, and compelling animal behavioral data. The complete absence of human evidence means all extrapolation to human effects is hypothesis rather than established finding.

Researchers studying synaptogenesis, HGF/c-Met signaling, and cognitive enhancement mechanisms can review Dihexa product specifications at Blackwell BioLabs. All batches are third party tested with HPLC purity confirmation and mass spectrometry identity verification.